Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Protalix BioTherapeutics, Inc.
- 4.3%
- 3.5M
- 6.18
Float 81.19M · Signal8 dilution snapshot · Nov 10, 2026
The cost to borrow PLX shares for a short sale and how many shares are available to borrow, refreshed through the session.
- 43.0%
- 8.3K
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 3.5M sh |
| Oct 15, 2026 | 3.5M sh |
| Sep 30, 2026 | 3.0M sh |
| Sep 15, 2026 | 2.9M sh |
| Aug 31, 2026 | 3.2M sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 20, 2026 | 8.3K sh |
| Oct 19, 2026 | 2.0K sh |
| Oct 5, 2026 | 2.1K sh |
| Oct 1, 2026 | 1.5K sh |
| Sep 24, 2026 | 2.5K sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 18, 2026 | 43.0% |
| Nov 17, 2026 | 34.3% |
| Nov 16, 2026 | 38.1% |
| Nov 13, 2026 | 19.8% |
| Nov 12, 2026 | 17.7% |
130 calendar days requested; 92 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for PLX: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 3,480,033 PLX shares were sold short (4.29% of a 81.19M-share float, 6.18 days to cover).